Actualités bibliographiques

2024

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma

Rey V, Tornín J, Alba-Linares JJ, Robledo C, Murillo D, Rodríguez A, Gallego B, Huergo C, Viera C, Braña A, Astudillo A, Heymann D, Szuhai K, Bovée JVMG, Fernández AF, Fraga MF, Alonso J, Rodríguez R.

Journal: EBioMedicine

Année: apr 2024

Volume: 102

https://doi.org/10.1016/j.ebiom.2024.105090

Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study

Jeka S, Dokoupilová E, Kivitz A, Żuchowski P, Vogg B, Krivtsova N, Sekhar S, Banerjee S, Schwebig A, Poetzl J, Body JJ, Eastell R

Journal: J Bone Miner Res.

Année: apr 2024

Volume: 39 Issue 3

Pages: 202-210

https://doi.org/10.1093/jbmr/zjae016

Long-term Outcomes and Patterns of Relapse Following High-dose Elective Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Nodes in Prostate Cancer: OLIGOPELVIS (GETUG-P07)

Vaugier L, Morvan C, Pasquier D, Buthaud X, Magné N, Beckendorf V, Sargos P, Crehange G, Pommier P, Loos G, Hasbini A, Latorzeff I, Silva M, Paul J, Blanc-Lapierre A, Supiot S.

Journal: Eur Urol.

Année: mar 2024

https://doi.org/10.1016/j.eururo.2024.02.013

Identification of MCM4 and PRKDC as new regulators of osteosarcoma cell dormancy based on 3D cell cultures

Jubelin C, Muñoz-Garcia J, Ollivier E, Cochonneau D, Vallette F, Heymann MF, Oliver L, Heymann D.

Journal: Biochim Biophys Acta Mol Cell Res.

Année: mar 2024

Volume: 1871, Issue 3

https://doi.org/10.1016/j.bbamcr.2024.119660

Guiding principles on the education and practice of theranostics

Pascual TNB, Paez D, Iagaru A, Gnanasegaran G, Lee ST, Sathekge M, Buatti JM, Giammarile F, Al-Ibraheem A, Pardo MA, Baum RP, De Bari B, Ben-Haim S, Blay JY, Brink A, Estrada-Lobato E, Fanti S, Golubic AT, Hatazawa J, Israel O, Kiess A, Knoll P, Louw L, Mariani G, Mirzaei S, Orellana P, Prior JO, Urbain JL, Vichare S, Vinjamuri S, Virgolini I, Scott AM.

Journal: Eur J Nucl Med Mol Imaging

Année: mar 2024

Volume: 51

Pages: 2320-2331

https://doi.org/10.1007/s00259-024-06657-2

Stereotactic body radiation therapy for bone oligometastases

Naessens C, Chamois J, Supiot S, Faivre JC, Arnaud A, Thureau S.

Journal: Cancer/Radiothérapie

Année: feb 2024

Volume: 28, Issue 1

Pages: 111-118

https://doi.org/10.1016/j.canrad.2023.04.006

Management of head and neck carcinomas with synchronous or metachronous oligometastatic disease: Role of locoregional radiotherapy and metastasis-directed radiotherapy

Tonneau M, Nebbache R, Larnaudie A, Thureau S, Pointreau Y, Blanchard P, Thariat J.

Journal: Cancer/Radiothérapie

Année: feb 2024

Volume: 28, Issue 1

Pages: 83-92

https://doi.org/10.1016/j.canrad.2023.03.004

A Score to Predict the Clinical Usefulness of Therapeutic Drug Monitoring: Application to Oral Molecular Targeted Therapies in Cancer

Géraud A, Combarel D, Funck-Brentano C, Beaulieu Q, Zahr N, Broutin S, Spano JP, Massard C, Besse B, Gougis P.

Journal: Clin Pharmacol Ther.

Année: feb 2024

https://doi.org/10.1002/cpt.3193

Is oligometastatic disease an applicable and useful concept in haematologic malignancies? A narrative review of radiation therapy standards, modern techniques, and innovations

Ollivier L, Debbi K, To NH, Cailleteau A, Supiot S, Mervoyer A, Guimas V, Belkacémi Y.

Journal: Cancer/Radiothérapie

Année: feb 2024

Volume: 28, Issue 1

Pages: 119-130

https://doi.org/10.1016/j.canrad.2023.08.008

The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies

Miszczyk M, Rajwa P, Yanagisawa T, Nowicka Z, Shim SR, Laukhtina E, Kawada T, von Deimling M, Pradere B, Rivas JG, Gandaglia G, van den Bergh RCN, Goldner G, Supiot S, Zilli T, Trinh QD, Nguyen PL, Briganti A, Ost P, Ploussard G, Shariat SF

Journal: Eur Urol.

Année: feb 2024

Volume: 85, Issue 2

Pages: 125-138

https://doi.org/10.1016/j.eururo.2023.10.012